|1.||Pinna, Annalisa: 6 articles (05/2014 - 06/2002)|
|2.||Morelli, Micaela: 4 articles (08/2007 - 06/2002)|
|3.||Schwarzschild, Michael A: 3 articles (03/2013 - 01/2005)|
|4.||Parker, Eric M: 2 articles (04/2014 - 10/2008)|
|5.||Hodgson, Robert A: 2 articles (04/2014 - 10/2008)|
|6.||Chen, Jiang-Fan: 2 articles (03/2013 - 12/2006)|
|7.||Cristalli, Gloria: 2 articles (06/2009 - 04/2005)|
|8.||Volpini, Rosaria: 2 articles (06/2009 - 04/2005)|
|9.||Wardas, Jadwiga: 2 articles (11/2005 - 07/2002)|
|10.||Aalizadeh, R: 1 article (06/2015)|
|1.||Parkinson Disease (Parkinson's Disease)
07/01/2005 - "Adenosine A2A receptor antagonists are orally effective in a variety of rodent models of Parkinson's disease. "
04/05/2014 - "Adenosine A2A receptor antagonists have been evaluated as a novel treatment for Parkinson's disease and have demonstrated efficacy in a broad spectrum of pharmacological and toxicological rodent and primate models. "
06/01/2015 - "Recently, adenosine A2A receptor antagonists have been identified as a drug target for the treatment of Parkinson's disease. "
08/20/2014 - "Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease."
08/01/2014 - "Adenosine A2A receptor antagonists in Parkinson's disease: still in the running."
09/01/2008 - "Acute administration of the adenosine A2A receptor antagonists CSC or MSX-3 at the highest doses tested (5 and 1.25mg/kg, respectively) significantly reduces haloperidol-induced catalepsy. "
06/01/1999 - "Adenosine A1, A2A, and A3 receptor agonists potentiated, whereas adenosine A2A receptor antagonists, but not A1 antagonists, reversed 3alpha, 5alpha THP-induced catalepsy. "
10/01/2008 - "Preclinical studies in the rat have demonstrated that adenosine A2A receptor antagonists can attenuate behaviors reflecting reduced dopamine activity, such as haloperidol-induced catalepsy and hypoactivity. "
01/01/2014 - "Second, effects of adenosine A2A receptor antagonists on dyskinesia were described. "
08/01/2012 - "Preclinical animal models have shown the ability of adenosine A2A receptor antagonists to improve PD motor symptoms, reduce motor fluctuations and dyskinesia, as well as protect against toxin-induced neuronal degeneration. "
05/12/1999 - "Adenosine A2A receptor antagonists have antiparkinsonian effects of their own with a reduced propensity to elicit dyskinesias. "
03/01/2013 - "Adenosine A2A receptor antagonists reduce or prevent the development of dyskinesia in animal models of levodopa-induced dyskinesia. "
04/01/1998 - "These results suggest that selective adenosine A2A receptor antagonists represent a new class of antiparkinsonian agents that improve disability without producing hyperactivity and without inducing dyskinesia."
12/20/1995 - "However, since administered CSC has no effect on the reestablishment of postischemic blood flow, treatment of stroke with adenosine A2A receptor antagonists may not be advisable. "
12/24/1995 - "These results suggest that adenosine A2a receptor antagonists may be useful for the prevention of cerebral injuries resulting from stroke or cardiac arrest."
|5.||Movement Disorders (Movement Disorder)
01/01/2014 - "Adenosine A2A receptor antagonists are classified to be a recent new therapeutic strategy for the symptomatic treatment of Parkinson's disease, a hypokinetic movement disorder. "
10/01/2008 - "The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates."
|4.||Levodopa (L Dopa)
|5.||Caffeine (No Doz)
|6.||Purinergic P1 Receptors (Adenosine Receptor)
|7.||Oxidopamine (6 Hydroxydopamine)
|8.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)